{"id":"acs-patients-treated-with-oap","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Hyperkalemia"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Cough"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"OAP works by blocking the action of angiotensin II and neprilysin, leading to vasodilation and reduced blood pressure. This mechanism is thought to be beneficial in patients with heart failure.","oneSentence":"OAP is an angiotensin receptor-neprilysin inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:18:50.585Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of heart failure"}]},"trialDetails":[{"nctId":"NCT02271022","phase":"","title":"Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-02-17","conditions":"Acute Coronary Syndromes","enrollment":2000},{"nctId":"NCT02190123","phase":"","title":"REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets (OAP) in Patients With Acute Coronary Syndrome (ACS) in Be/Lux.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09","conditions":"Treatment of Acute Coronary Syndrome (ACS).","enrollment":430}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ACS patients treated with OAP","genericName":"ACS patients treated with OAP","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OAP is an angiotensin receptor-neprilysin inhibitor. Used for Treatment of heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}